**FOI Ref: 6338**

**Category(ies): Clinical – Service Activity**

**Subject: Diabetic Retinopathy Patients**

**Date Received: 12/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| \*Please break down by hospital within your trust | |
| 1. How many current diabetic retinopathy (including DMO) patients do you have? \* | It is not possible to get the number of DMO patients. It has been discussed at CSU level that we have been trying to pull a report of all diabetic patients that are under ophthalmology, but at this time it is not available. |
| 1. How many diabetic retinopathy (including DMO) patients do you have that are currently being monitored and held at "wait and see" but not yet progressed to needing any treatments (injections/laser/implant)? \* |
| 1. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)? \* | 1078 |
| 1. How many diabetic retinopathy (including DMO) patients do you have that have received treatment (injections/laser/implants) in the year April 2020-March 2021 inclusive (i.e. during COVID-19)? \* | 1297 |
| 1. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2019-March 2020 inclusive (i.e. pre COVID-19)? Please break down by treatment. \* | Aflicercept (Eylea) - 278  Ranzibizumab (Lucentis) - 783  Dexamethasone - 12  Fluocinolone - 5 |
| 1. How many injections (Avastin/bevacizumab, Eylea/aflibercept, Lucentis/ranibizumab) have been used for diabetic retinopathy (including DMO) patients in the year April 2020-March 2021 inclusive (i.e. pre COVID-19)? Please break down by treatment. \* | Aflicercept (Eylea) - 471  Ranzibizumab (Lucentis) - 819  Dexamethasone - 4  Fluocinolone - 3 |